203 related articles for article (PubMed ID: 35166238)
1. Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.
Lim SA; Zhou J; Martinko AJ; Wang YH; Filippova EV; Steri V; Wang D; Remesh SG; Liu J; Hann B; Kossiakoff AA; Evans MJ; Leung KK; Wells JA
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166238
[TBL] [Abstract][Full Text] [Related]
2. Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers.
Donahue KL; Pasca di Magliano M
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166242
[TBL] [Abstract][Full Text] [Related]
3. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
[No Abstract] [Full Text] [Related]
4. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
[TBL] [Abstract][Full Text] [Related]
5. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
Moroz A; Wang YH; Sharib JM; Wei J; Zhao N; Huang Y; Chen Z; Martinko AJ; Zhuo J; Lim SA; Zhang LH; Seo Y; Carlin S; Leung KK; Collisson EA; Kirkwood KS; Wells JA; Evans MJ
Clin Cancer Res; 2020 Jul; 26(14):3608-3615. PubMed ID: 32341034
[TBL] [Abstract][Full Text] [Related]
6. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
7. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer.
Chopra S; Trepka K; Sakhamuri S; Carretero-González A; Zhu J; Egusa E; Zhou J; Leung K; Zhao N; Hooshdaran N; Feng FY; Wells JA; Chou J; Evans MJ
Clin Cancer Res; 2023 Apr; 29(7):1232-1242. PubMed ID: 36648492
[TBL] [Abstract][Full Text] [Related]
8. Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1.
He Y; Reid JC; He H; Harrington BS; Finlayson B; Khan T; Hooper JD
Biol Chem; 2018 Sep; 399(9):1091-1097. PubMed ID: 29447112
[TBL] [Abstract][Full Text] [Related]
9. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer-Letter.
Birnbaum DJ; Finetti P; Birnbaum D; Bertucci F
Clin Cancer Res; 2020 Oct; 26(20):5539. PubMed ID: 33060289
[No Abstract] [Full Text] [Related]
10. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.
He Y; Wortmann A; Burke LJ; Reid JC; Adams MN; Abdul-Jabbar I; Quigley JP; Leduc R; Kirchhofer D; Hooper JD
J Biol Chem; 2010 Aug; 285(34):26162-73. PubMed ID: 20551327
[TBL] [Abstract][Full Text] [Related]
11. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation.
Miyazawa Y; Uekita T; Hiraoka N; Fujii S; Kosuge T; Kanai Y; Nojima Y; Sakai R
Cancer Res; 2010 Jun; 70(12):5136-46. PubMed ID: 20501830
[TBL] [Abstract][Full Text] [Related]
12. Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.
Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala JK; Dreyer T; Magdolen V; Reuning U; He Y; Tate EW; Hooper JD
Nat Chem Biol; 2021 Jul; 17(7):776-783. PubMed ID: 33859413
[TBL] [Abstract][Full Text] [Related]
13. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.
Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ
Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208
[TBL] [Abstract][Full Text] [Related]
15. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
16. The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
Dong Y; He Y; de Boer L; Stack MS; Lumley JW; Clements JA; Hooper JD
J Biol Chem; 2012 Mar; 287(13):9792-9803. PubMed ID: 22315226
[TBL] [Abstract][Full Text] [Related]
17. CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.
Leroy C; Shen Q; Strande V; Meyer R; McLaughlin ME; Lezan E; Bentires-Alj M; Voshol H; Bonenfant D; Alex Gaither L
Oncogene; 2015 Oct; 34(44):5593-8. PubMed ID: 25728678
[TBL] [Abstract][Full Text] [Related]
18. The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.
Benes CH; Poulogiannis G; Cantley LC; Soltoff SP
Oncogene; 2012 Feb; 31(5):653-63. PubMed ID: 21725358
[TBL] [Abstract][Full Text] [Related]
19. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma.
Uekita T; Tanaka M; Takigahira M; Miyazawa Y; Nakanishi Y; Kanai Y; Yanagihara K; Sakai R
Am J Pathol; 2008 Jun; 172(6):1729-39. PubMed ID: 18467693
[TBL] [Abstract][Full Text] [Related]
20. CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression.
Saponaro M; Flottmann S; Eckstein M; Hommerding O; Klümper N; Corvino D; Hosni S; Schmidt A; Mönig N; Schmidt D; Ellinger J; Toma M; Kristiansen G; Bald T; Alimonti A; Ritter M; Hölzel M; Alajati A
Sci Rep; 2023 Jan; 13(1):73. PubMed ID: 36593286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
